Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Alpha-Acetyl-3,5-Diiodotyrosylglycine is a synthetic dipeptide derivative of tyrosine and glycine in which the tyrosine residue is acetylated at the alpha-amino group and iodinated at positions 3 and 5 of the phenolic ring. It is classified as a small molecule and has been studied primarily as an experimental compound. There are no approved indications or known clinical uses for this molecule. Its mechanism of action has not been established in published literature or drug databases[1][4][9]. The compound's structure suggests it may be used in research related to iodinated peptides or thyroid hormone analogs due to its structural similarity to iodinated tyrosines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-Alpha-Acetyl-3,5-Diiodotyrosylglycine.